Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Given Average Recommendation of “Hold” by Analysts

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) has received an average recommendation of “Hold” from the five research firms that are currently covering the stock, Marketbeat.com reports. Five analysts have rated the stock with a hold rating. The average 12 month price target among analysts that have covered the stock in the last year is $39.25.

CALT has been the topic of a number of recent analyst reports. Lifesci Capital cut Calliditas Therapeutics AB (publ) from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 28th. Jefferies Financial Group reiterated a “hold” rating and set a $39.00 price target (down from $58.00) on shares of Calliditas Therapeutics AB (publ) in a report on Tuesday, May 28th. HC Wainwright reissued a “neutral” rating and set a $39.00 price objective on shares of Calliditas Therapeutics AB (publ) in a research report on Tuesday, May 28th. Citigroup reaffirmed a “neutral” rating and issued a $39.00 target price on shares of Calliditas Therapeutics AB (publ) in a research report on Friday, May 31st. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $40.00 price target (down from $55.00) on shares of Calliditas Therapeutics AB (publ) in a research report on Tuesday, May 28th.

Calliditas Therapeutics AB (publ) Stock Up 1.3 %

NASDAQ CALT opened at $39.32 on Wednesday. The business’s fifty day simple moving average is $38.93 and its 200-day simple moving average is $28.46. The company has a quick ratio of 2.62, a current ratio of 2.69 and a debt-to-equity ratio of 8.46. The firm has a market cap of $1.17 billion, a PE ratio of -21.25 and a beta of 1.77. Calliditas Therapeutics AB has a 52 week low of $15.25 and a 52 week high of $41.90.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last issued its earnings results on Tuesday, August 13th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.09. Calliditas Therapeutics AB (publ) had a negative net margin of 40.19% and a negative return on equity of 160.87%. The company had revenue of $52.36 million for the quarter, compared to the consensus estimate of $42.89 million. During the same period in the previous year, the firm earned ($0.33) earnings per share. As a group, equities analysts anticipate that Calliditas Therapeutics AB will post -0.86 earnings per share for the current year.

Hedge Funds Weigh In On Calliditas Therapeutics AB (publ)

A hedge fund recently bought a new stake in Calliditas Therapeutics AB (publ) stock. Optiver Holding B.V. acquired a new stake in Calliditas Therapeutics AB (publ) (NASDAQ:CALT) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 980 shares of the company’s stock, valued at approximately $25,000. 2.83% of the stock is owned by institutional investors and hedge funds.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.